Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
Months after FDA rejection, Sanofi touts pivotal win for rare disease drug sutimlimab as it preps to refile
One of the pillar drugs of Sanofi’s $11.6 billion pickup of Bioverativ hit a big setback late last year when the FDA sent its application …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
